Selected article for: "AKI acute kidney injury and chronic kidney disease"
Author: Ng, Jia H.; Bijol, Vanesa; Sparks, Matthew A.; Sise, Meghan E.; Izzedine, Hassane; Jhaveri, Kenar D.
Title: Pathophysiology of Acute Kidney Injury in Patients with COVID-19
  • Cord-id: vhd7ahsc
  • Document date: 2020_10_20
    • ID: vhd7ahsc
    Snippet: Acute kidney injury (AKI) is common among hospitalized patients with Coronavirus Infectious Disease 2019 (COVID-19), with the occurrence of AKI ranging from 0.5% to 80%. The variability in the occurrence of AKI has been attributed to the difference in geographic locations, race/ethnicity, and severity of illness. AKI among hospitalized patients is associated with increased length of stay and in-hospital deaths. Even patients with AKI who survive to hospital discharge are at risk of developing ch
    Document: Acute kidney injury (AKI) is common among hospitalized patients with Coronavirus Infectious Disease 2019 (COVID-19), with the occurrence of AKI ranging from 0.5% to 80%. The variability in the occurrence of AKI has been attributed to the difference in geographic locations, race/ethnicity, and severity of illness. AKI among hospitalized patients is associated with increased length of stay and in-hospital deaths. Even patients with AKI who survive to hospital discharge are at risk of developing chronic kidney disease (CKD) or end-stage kidney disease (ESKD). An improved knowledge of the pathophysiology of AKI in COVID-19 is crucial to mitigate and manage AKI and to improve the survival of patients who developed AKI during COVID-19. The goal of this article is to provide our current understanding of the etiology and the pathophysiology of AKI in the setting of COVID-19.

    Search related documents:
    Co phrase search for related documents
    • academic hospital and acute ards respiratory distress syndrome: 1
    • academic hospital and acute kidney injury: 1, 2, 3, 4, 5, 6, 7
    • academic hospital and live patient: 1
    • academic hospital and liver cirrhosis: 1
    • academic hospital and lopinavir ritonavir: 1
    • activation immune and acute aki kidney injury: 1, 2, 3, 4, 5, 6, 7, 8
    • activation immune and acute ards respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • activation immune and acute kidney injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • activation immune and acute tubular injury: 1
    • activation immune and liver cirrhosis: 1, 2, 3, 4, 5
    • activation immune and lopinavir ritonavir: 1, 2, 3, 4
    • acute aki kidney injury and liver cirrhosis: 1, 2, 3
    • acute aki kidney injury and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8
    • acute ards respiratory distress syndrome and liver cirrhosis: 1, 2
    • acute ards respiratory distress syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute kidney injury and liver cirrhosis: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute kidney injury and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18